Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial

Claudia Colomba; Antonio Cascio; Lucina Titone Lanza Di Scalea; Lucio Di Martino

Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial

Claudia Colomba, Antonio Cascio, Lucina Titone Lanza Di Scalea, Lucio Di Martino

Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”

Risultato della ricerca: Article

42 Citazioni (Scopus)

Abstract

Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF

Lingua originale	English
pagine (da-a)	409-411
Numero di pagine	3
Rivista	Clinical Infectious Diseases
Volume	33
Stato di pubblicazione	Published - 2001

Fingerprint

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

Cita questo

Colomba, C., Cascio, A., Titone Lanza Di Scalea, L., & Di Martino, L. (2001). Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial. Clinical Infectious Diseases, 33, 409-411.

@article{2b6e8657aa4145148797188f67e99f0d,

title = "Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial",

abstract = "Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF",

keywords = "clarithromycin Mediterranean spotted fever, clarithromycin Mediterranean spotted fever",

author = "Claudia Colomba and Antonio Cascio and {Titone Lanza Di Scalea}, Lucina and {Di Martino}, Lucio",

year = "2001",

language = "English",

volume = "33",

pages = "409--411",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial

AU - Colomba, Claudia

AU - Cascio, Antonio

AU - Titone Lanza Di Scalea, Lucina

AU - Di Martino, Lucio

PY - 2001

Y1 - 2001

N2 - Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF

AB - Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF

KW - clarithromycin Mediterranean spotted fever

UR - http://hdl.handle.net/10447/63391

M3 - Article

VL - 33

SP - 409

EP - 411

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -

Accesso al documento

OA Link